Last updated: August 3, 2026
Amoxicillin and clavulanate potassium is a mature, genericized antibacterial combination with limited active-ingredient patent value. Commercial differentiation depends on formulation performance, pediatric acceptability, stability, dosing convenience, manufacturing cost, supply reliability, and regulatory execution. The strongest opportunities are high-concentration pediatric suspensions, taste-masked dispersible products, moisture-controlled tablets, ready-to-use hospital presentations, and region-specific products that improve storage and administration.
What is the market and regulatory status of amoxicillin and clavulanate potassium?
Amoxicillin and clavulanate potassium combines the beta-lactam antibiotic amoxicillin with clavulanate, a beta-lactamase inhibitor. Clavulanate extends amoxicillin activity against organisms that produce certain beta-lactamases.
The combination is marketed in oral tablets, chewable tablets, oral suspensions, extended-release tablets in some markets, and intravenous presentations. Augmentin was the originator brand associated with GlaxoSmithKline. The product is now supplied through multiple generic manufacturers and distributors.
Key dosage forms and strengths
| Dosage form |
Common strength expression |
Primary excipient challenge |
| Immediate-release tablet |
250/125 mg, 500/125 mg, 875/125 mg |
Moisture protection, content uniformity, disintegration |
| Chewable tablet |
125/31.25 mg, 200/28.5 mg, 250/62.5 mg, 400/57 mg |
Taste masking, mouthfeel, mechanical strength |
| Powder for oral suspension |
125/31.25 mg per 5 mL, 200/28.5 mg per 5 mL, 250/62.5 mg per 5 mL, 400/57 mg per 5 mL |
Reconstitution, sedimentation, flavor, stability |
| Extended-release tablet |
Commonly 1,000/62.5 mg |
Controlled release and dose uniformity |
| Intravenous powder |
Market-specific ratios, including 500/100 mg and 1,000/200 mg |
Reconstitution, infusion compatibility, sterility |
The exact formulation and excipient profile vary by manufacturer and jurisdiction. FDA-approved labels identify the inactive ingredients for each product presentation [1].
When does amoxicillin and clavulanate potassium lose exclusivity?
The core active-ingredient protection for amoxicillin and clavulanate potassium is expired. The combination is a small-molecule product and is not subject to biosimilar competition. Generic entry is legally available through abbreviated new drug applications, subject to product-specific requirements.
The commercial protection remaining in this category is primarily formulation-based. Potentially relevant rights may cover:
- Modified-release tablets
- High-concentration suspension systems
- Taste-masking technologies
- Stabilized clavulanate compositions
- Moisture-resistant packaging
- Specific crystal forms or particle-size distributions
- Manufacturing processes
- Fixed-ratio combinations
- New pediatric or administration methods
The original Augmentin composition is no longer a meaningful exclusivity barrier. A new formulation may still receive patent protection if it contains a novel, non-obvious composition or process and meets statutory patent requirements.
What is the Orange Book status of amoxicillin and clavulanate potassium?
The FDA Orange Book lists approved reference and generic products for amoxicillin and clavulanate potassium. Historical product-specific patents and exclusivity periods associated with the originator have expired or ceased to be significant barriers to conventional generic entry.
An applicant developing a conventional immediate-release tablet or suspension therefore faces a standard generic pathway rather than an originator-controlled market. A formulation with a new release profile, new delivery system, or distinct clinical use may require a different regulatory strategy, including a 505(b)(2) application where applicable [2].
What excipients are used in amoxicillin and clavulanate potassium products?
Excipient selection is driven by the different stability and performance requirements of amoxicillin and clavulanate potassium. Clavulanate is particularly sensitive to moisture and degradation conditions. Oral products must balance chemical stability with rapid drug release.
Tablet excipients
Immediate-release tablets commonly use combinations of:
- Microcrystalline cellulose as a diluent and compression aid
- Sodium starch glycolate or another superdisintegrant
- Colloidal silicon dioxide as a glidant
- Magnesium stearate as a lubricant
- Hypromellose or another film former
- Titanium dioxide or approved colorants
- Plasticizers such as polyethylene glycol or triethyl citrate in the film coat
The formulation objective is rapid disintegration without excessive exposure to humidity during manufacture or storage. High-dose tablets also require strong blend uniformity because the amoxicillin-to-clavulanate ratio is fixed and the clavulanate fraction is comparatively small.
Chewable-tablet excipients
Chewable products require a different excipient architecture. Common functions include:
- Mannitol or sorbitol for bulk and cooling mouthfeel
- Microcrystalline cellulose for structure
- Crospovidone or sodium starch glycolate for breakup
- Flavor systems for bitterness reduction
- Sweeteners such as aspartame, sucralose, or saccharin derivatives
- Colloidal silicon dioxide for flow
- Magnesium stearate or equivalent lubricant
Clavulanate and amoxicillin both create taste challenges, but the combination is especially difficult for pediatric use because the formulation contains a high antibiotic load and must be administered repeatedly over several days.
Oral suspension excipients
Suspensions usually contain:
- Suspending agents such as xanthan gum
- Wetting and dispersing agents
- Sweeteners
- Fruit or berry flavor systems
- Buffers or pH modifiers
- Silicon dioxide or other viscosity-control materials
- Preservatives where permitted and needed
- Bulking agents such as mannitol
- Antifoaming or processing aids in some formulations
After reconstitution, the product must maintain dose uniformity during the full labeled in-use period. The suspension must redisperse readily after standing and must not form a hard cake at the bottom of the bottle.
What formulation patents could protect new amoxicillin-clavulanate products?
The most defensible patent opportunities concern technical problems that are difficult to solve with routine excipient substitution.
Moisture-stable tablets
A formulation could seek protection for a low-moisture tablet core combined with a high-barrier coating and moisture-protective packaging. Potential claim elements include:
- Defined water activity
- Specific tablet-core composition
- Controlled residual moisture
- Desiccant-containing packaging
- Blister structures with low water-vapor transmission
- Stability performance under accelerated conditions
The commercial value is highest in hot and humid markets where product degradation, discoloration, or potency loss can reduce shelf life.
High-concentration pediatric suspensions
The 400/57 mg per 5 mL suspension reduces dosing volume compared with lower-strength presentations. This can improve adherence and caregiver acceptance, but it increases formulation difficulty.
Potential protected features include:
- A high-solids suspension with controlled viscosity
- A specific xanthan-gum or polymer network
- Improved redispersibility
- Reduced sedimentation
- Stable flavor and sweetener systems
- Lower reconstitution volume
- Defined particle-size distribution
- Extended in-use stability after reconstitution
A high-concentration suspension can create a practical barrier even when the active ingredients are unprotected because bioequivalence, microbiological quality, dosing uniformity, and palatability must all be demonstrated.
Taste-masked dispersible tablets
A dispersible or orally disintegrating product could target children who cannot swallow tablets but reject conventional suspensions. Commercially valuable approaches include:
- Ion-exchange resin complexes
- Polymer coatings
- Lipid barriers
- Spray-dried drug particles
- Effervescent dispersion systems
- Multiparticulate granules
- Flavor systems that reduce aftertaste
The key regulatory risk is that taste masking can slow dissolution or alter exposure. The product must preserve rapid amoxicillin release and appropriate clavulanate delivery.
Ready-to-use liquid products
A ready-to-use suspension would eliminate reconstitution errors and reduce caregiver burden. The technical challenge is maintaining chemical and microbiological stability in an aqueous environment. Water promotes degradation and may require a fundamentally different stabilizer, preservative, container, and pH system.
A successful product could command a premium in pediatric, urgent-care, and outpatient settings, but it would face a higher stability and packaging burden than a conventional dry powder.
How should manufacturers design the excipient strategy?
The strongest development strategy separates the product into four risk domains: stability, dose delivery, acceptability, and manufacturability.
Stability strategy
Clavulanate protection should guide early formulation work. Priority controls include:
- Low-moisture raw materials and controlled humidity during blending.
- Moisture-resistant primary packaging.
- Particle-size control to reduce segregation.
- Compatibility testing for sweeteners, flavors, polymers, and lubricants.
- Accelerated and long-term stability testing in the intended climate zones.
- Defined reconstitution and in-use stability protocols for suspensions.
The packaging system is part of the formulation strategy. High-barrier aluminum-aluminum blisters, desiccant bottles, induction seals, and low-permeability polymer containers can be commercially important even when the tablet composition is conventional.
Suspension performance strategy
Suspension development should measure more than appearance. Relevant performance parameters include:
- Sedimentation rate
- Redispersibility after defined standing times
- Delivered dose uniformity
- Viscosity across temperature ranges
- Pourability
- Syringeability
- Reconstitution time
- Foaming
- Microbial limits
- Chemical stability after reconstitution
A formulation that is physically stable but difficult to pour can fail in practice. A highly viscous suspension can also cause inaccurate dosing through oral syringes.
Pediatric acceptability strategy
Taste masking has direct commercial value because poor taste can reduce adherence and create demand for alternative antibiotics. The formulation should be evaluated with age-appropriate sensory methods rather than relying only on adult panels.
The leading commercial variables are:
- Bitterness intensity
- Lingering aftertaste
- Sweetness profile
- Flavor fatigue over repeated doses
- Mouth coating
- Ease of swallowing
- Required dose volume
Mannitol can provide a cooling sensation, while sucrose, sorbitol, and high-intensity sweeteners create different tolerability and labeling profiles. Sugar-free products may be preferable for some markets, but polyols can cause gastrointestinal effects at higher exposure.
What commercial opportunities exist for generic manufacturers?
High-concentration pediatric suspension
This is the clearest formulation opportunity. A product that reduces dose volume, resuspends quickly, tastes better, and remains stable in hot climates can compete on pharmacy substitution, caregiver preference, and institutional purchasing.
Unit-dose and ready-to-administer formats
Hospitals and outpatient clinics may value:
- Oral syringes prefilled with common doses
- Unit-dose powder sachets
- Small-volume reconstitution bottles
- Ready-to-use oral liquids
- IV premix bags where stability permits
These formats can reduce medication errors and pharmacy compounding labor.
Premium moisture-protected tablets
A generic tablet with a stronger stability profile can target markets with weak temperature and humidity control. Commercial differentiation may come from longer shelf life, robust packaging, and fewer product complaints rather than a novel pharmacological benefit.
Pediatric taste and administration platforms
A dispersible granule, chewable tablet, or flavored powder can address children who refuse suspensions or cannot swallow tablets. This strategy may support a branded-generic position even where price competition is intense.
Contract manufacturing and licensing
Licensing opportunities are more likely to involve:
- Taste-masking technology
- Pediatric multiparticulates
- High-barrier packaging
- Spray-drying or microencapsulation
- Stabilized suspension platforms
- Hospital-ready presentations
The active ingredients themselves are commodity inputs. The transferable value lies in the formulation process, excipient system, analytical method, and regulatory dossier.
Which companies compete in the amoxicillin-clavulanate market?
Competition includes originator-linked products, national generic manufacturers, regional pharmaceutical companies, and contract manufacturers. Generic suppliers commonly compete on:
- Acquisition cost
- API supply security
- Manufacturing scale
- Product availability
- Pediatric dosage breadth
- Formulation stability
- Regulatory approvals across multiple markets
The market is exposed to supply disruption because amoxicillin production depends on fermentation capacity, specialized intermediates, and regulated pharmaceutical manufacturing. Clavulanate adds a second supply chain and creates ratio-specific formulation requirements.
Manufacturers with validated dual-source API arrangements, strong beta-lactam containment capability, and reliable pediatric suspension production have an operational advantage.
What generic entry risks exist for new products?
A conventional immediate-release generic faces price erosion and rapid substitution. The principal risks are:
- Limited differentiation from existing ANDA products
- Pharmacy preference for established suppliers
- Shortage-driven procurement volatility
- Clavulanate degradation during storage
- Failure to match reference-product dissolution
- Inadequate suspension dose uniformity
- Poor taste acceptance
- Packaging-related stability failures
- Supply-chain interruption for either active ingredient
A formulation patent can slow direct copying, but it cannot prevent competition from products using different excipient systems unless the claims are broad and enforceable.
How strong is the patent estate for amoxicillin and clavulanate potassium?
The core patent estate is weak because the active ingredients and conventional combination products are long established. A new product can obtain meaningful protection only through a technically specific formulation, process, device, or use.
| Protection category |
Commercial strength |
| Amoxicillin composition patents |
Minimal for new market entry |
| Clavulanate composition patents |
Minimal for conventional products |
| Conventional immediate-release tablets |
Low |
| High-concentration suspension |
Moderate if stability and performance are demonstrated |
| Taste-masked pediatric system |
Moderate to high if technically differentiated |
| Moisture-protective packaging |
Moderate, usually narrow |
| Modified-release product |
Potentially high if clinically and technically validated |
| Manufacturing process |
Moderate, dependent on detectability and claim scope |
| Method-of-use patent |
Limited for established indications |
Patent strength should be assessed claim by claim. A formulation patent that merely recites routine excipients at broad concentration ranges is vulnerable to validity challenges. Claims tied to unexpected stability, dissolution, taste, or pharmacokinetic results have a stronger commercial basis.
What litigation and Paragraph IV issues affect this market?
Paragraph IV risk is most relevant when a new formulation patent is listed for a branded product or when an ANDA applicant challenges a surviving product-specific patent. For legacy immediate-release amoxicillin-clavulanate products, the main commercial issue is generic price competition rather than originator patent enforcement.
Potential disputes may involve:
- Whether an ANDA product infringes a formulation claim
- Whether the challenged patent is invalid for obviousness
- Whether the patent is properly listed
- Whether the generic formulation is materially different
- Whether a modified-release product requires a separate clinical bridge
- Whether a manufacturing process can be detected in the finished product
Settlement agreements can affect launch timing, but the commercial value of such settlements is limited for an old combination unless a new, protected delivery system is involved.
Is biosimilar competition relevant to amoxicillin and clavulanate potassium?
No. Amoxicillin and clavulanate potassium are small molecules, not biologics. The relevant competitive pathway is generic substitution through ANDAs or comparable national procedures, not biosimilar approval.
Regulatory strategy depends on the dosage form:
- Conventional tablets generally rely on pharmaceutical equivalence and bioequivalence.
- Oral suspensions require attention to particle size, dose uniformity, dissolution, and inactive ingredients.
- Modified-release products may require additional pharmacokinetic or clinical evidence.
- New pediatric delivery systems may qualify for a hybrid or 505(b)(2)-type pathway depending on jurisdiction and product design.
FDA inactive-ingredient requirements and the Inactive Ingredient Database provide an important framework for excipient selection, but they do not eliminate the need to establish formulation-specific safety and performance [2,3].
How does amoxicillin-clavulanate compare with competing antibiotics?
| Product |
Formulation opportunity |
Commercial constraint |
| Amoxicillin-clavulanate |
Pediatric suspension, taste masking, high concentration, stable tablets |
Mature generic market and gastrointestinal tolerability |
| Cefdinir |
Flavor and suspension differentiation |
Established pediatric competition |
| Cephalexin |
Low-cost suspension and capsule products |
Limited premium potential |
| Azithromycin |
Short-course liquid and dosing convenience |
Different resistance and indication profile |
| Piperacillin-tazobactam |
Hospital IV supply and premix systems |
Sterility and institutional procurement barriers |
Amoxicillin-clavulanate retains commercial relevance because of broad prescribing across respiratory, skin, dental, urinary, and other bacterial infections. Its principal weakness is tolerability, especially gastrointestinal adverse effects, which can limit premium positioning based solely on excipient improvement.
What is the revenue exposure and launch outlook?
Revenue exposure is concentrated in volume rather than patent-protected pricing. A new entrant should expect:
- Rapid price pressure for standard tablets
- Stronger margins for differentiated pediatric formats
- Institutional opportunities for reliable supply
- Regional pricing variation
- Higher value from shortage resilience than from active-ingredient exclusivity
The most credible launch scenarios are:
- A low-cost immediate-release generic with dependable supply.
- A high-concentration, better-tasting pediatric suspension.
- A moisture-stable tablet in high-humidity markets.
- A dispersible or chewable pediatric product.
- A hospital-focused unit-dose or ready-to-administer product.
The first scenario offers scale but limited margin. The second and third offer stronger differentiation. The fourth carries greater formulation and regulatory risk but may support a branded-generic price premium.
Key Takeaways
- Amoxicillin and clavulanate potassium has no meaningful core active-ingredient exclusivity barrier.
- The commercial opportunity is formulation-led, not molecule-led.
- Clavulanate stability, moisture control, and suspension performance are the main technical priorities.
- High-concentration pediatric suspensions offer the clearest near-term differentiation.
- Taste-masked dispersible products can address adherence and administration problems.
- Packaging is a critical part of the product strategy because moisture can affect stability.
- Conventional tablets face immediate price erosion after generic entry.
- Formulation patents can be valuable when supported by unexpected stability, dissolution, taste, or pharmacokinetic results.
- Biosimilar risk does not apply because the product is a small-molecule combination.
- Reliable API sourcing and beta-lactam manufacturing capacity may create more commercial advantage than additional narrow patents.
FAQs about amoxicillin-clavulanate excipient and formulation opportunities
Can a sugar-free amoxicillin-clavulanate suspension be commercialized?
Yes. A sugar-free suspension can use polyols and high-intensity sweeteners, but the formulation must address taste, viscosity, gastrointestinal tolerability, microbial quality, and dose uniformity.
Which excipient is most important for clavulanate stability?
No single excipient controls stability in every product. Moisture control, pH, packaging, particle characteristics, and the complete excipient system collectively determine clavulanate performance.
Is a high-concentration suspension automatically patentable?
No. Higher drug loading alone is unlikely to support strong patent protection. Patentability improves when the product demonstrates a non-obvious combination of concentration, viscosity, redispersibility, stability, dosing accuracy, or taste performance.
Can amoxicillin-clavulanate be sold as an orally disintegrating tablet?
Potentially, but the product must preserve rapid and consistent release while managing the large drug load and strong taste. Multiparticulate or dispersible technologies may be more practical than a conventional orally disintegrating tablet.
What is the best commercial niche for a new manufacturer?
A high-concentration pediatric suspension with improved taste, reliable redispersion, low-volume dosing, and climate-stable packaging offers the strongest balance of unmet need and technical feasibility.
References
-
U.S. Food and Drug Administration. (2023). Augmentin: Amoxicillin and clavulanate potassium prescribing information. DailyMed.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2024). Inactive ingredient database. Center for Drug Evaluation and Research.
-
World Health Organization. (2023). WHO model list of essential medicines: 23rd list. World Health Organization.
-
European Medicines Agency. (2024). Amoxicillin/clavulanic acid product information and regulatory guidance. European Medicines Agency.
